Vietnam Hemodialysis Vascular Grafts Market Analysis

Vietnam Hemodialysis Vascular Grafts Market Executive Summary

Vietnam Hemodialysis Vascular Grafts Market was valued at $1,050 Mn in 2023 and is predicted to grow at a CAGR of 5.33% from 2023 to 2030, to $1,510 Mn by 2030.

Hemodialysis vascular grafts are specialized devices crucial for establishing vascular access in patients, particularly those with end-stage renal disease undergoing hemodialysis. These grafts function as conduits, linking an artery to a vein to facilitate blood movement to and from the dialysis machine during treatment. They are designed to provide durable and reliable access, replacing or augmenting natural blood vessels that may not withstand the frequent punctures required in dialysis sessions. Common types include synthetic grafts made from materials like polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE), and biological grafts derived from treated animal tissue. Surgical implantation involves connecting the graft in the arm or leg, ensuring proper placement and meticulous care to maintain sufficient blood flow and mitigate complications such as infection or clotting.

Globally, around 700 Mn individuals are estimated to live with chronic kidney disease (CKD). When including acute kidney injury (AKI) and individuals requiring kidney failure treatments such as dialysis or transplantation, the prevalence of kidney diseases surpasses 850 Mn people worldwide, representing more than 10% of the global population.

The market therefore is driven by significant factors like the rising prevalence of chronic kidney disease, aging population, and technological advancements. However, limited healthcare infrastructure, developing reimbursement systems, and price sensitivity restrict the growth and potential of the market.

Prominent players in this field are W. L. Gore who offers the PROPATEN graft with a special heparin surface to fight clotting and the ACUSEAL graft designed for early use after implantation and C. R. Bard provides traditional ePTFE grafts and the innovative Vectra graft made from a different material that may allow for quicker access compared to standard options. Other contributors include Vascudyne, Inc., and LeMaitre among others.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Chronic Kidney Disease: Vietnam faces a growing burden of CKD, a major risk factor for ESRD requiring hemodialysis. Studies suggest a prevalence of CKD ranging from 8.3% to 10.3% in the adult population according to the Journal of Renal and Urology Research. This translates to a potentially large pool of individuals at risk of progressing to ESRD.

Government Health Initiatives: Government initiatives aimed at improving renal care and increasing access to dialysis treatments drive market growth. Programs that subsidize the cost of hemodialysis and support research into advanced vascular graft technologies contribute to market expansion by Vietnam Health Insurance, 2023.

Rising Urbanization: As Vietnam continues to urbanize, the prevalence of lifestyle-related health conditions contributing to CKD increases. Urban populations often experience higher rates of hypertension and diabetes, driving demand for hemodialysis and vascular grafts.

Market Restraints

Healthcare System Disparities: Disparities in healthcare access between urban and rural areas create challenges in distributing hemodialysis treatments and vascular grafts. Rural areas may face shortages of specialized healthcare facilities and resources.

Developing Reimbursement System: Vietnam's healthcare insurance system is still developing, and coverage for hemodialysis procedures and related materials like vascular grafts might be limited. This can create a financial burden for patients.

Cultural and Social Factors: Cultural beliefs and social attitudes towards medical treatments influence the adoption of hemodialysis vascular grafts. In some cases, traditional practices and reluctance to undergo medical procedures can impact treatment uptake.

Regulatory Landscape and Reimbursement Scenario

Vietnam's regulatory framework for medical devices, overseen by the Ministry of Health and the Drug Administration of Vietnam, categorizes hemodialysis vascular grafts into Class B, Class C, or Class D based on risk levels, influencing the depth of regulatory scrutiny required for market approval. Participation in the ASEAN Medical Device Harmonization Working Group aims to streamline approval processes for devices already endorsed in ASEAN member countries, though local-specific data may still be necessary.

Regarding reimbursement, Vietnam's social health insurance system, managed by Vietnam Social Security, covers part of the costs for hemodialysis treatments, but details regarding coverage for vascular grafts are not fully transparent, necessitating direct inquiries with VSS. This lack of clarity can result in substantial out-of-pocket expenses, potentially limiting access to necessary treatments.

Despite these challenges, the Vietnamese government has launched initiatives to support patients with chronic illnesses, potentially including subsidies or aid programs to alleviate financial burdens associated with hemodialysis and vascular graft procedures. These efforts underscore Vietnam's commitment to enhancing healthcare accessibility and affordability, despite ongoing complexities in regulatory and reimbursement frameworks.

Competitive Landscape

Key Players

Here are some of the major key players in the Vietnam Hemodialysis Vascular Grafts Market

• W. L. Gore & Associates, Inc.,
• C. R. Bard, Inc.,
• Vascudyne, Inc.,
• LeMaitre,
• Getinge AB,
• Vascular Genesis,
• InnAVasc Medical, Inc.
• CryoLife, Inc.
• Merit Medical Systems
• Biovic Sdn Bhd.